The change of APOA2 ATQ/AT subtype concentration caused by abnormal treatment of APOA2 homologous two terminal C terminal can be used to distinguish between early stage pancreatic cancer and high risk pancreatic cancer patients and healthy control group22. This evidence concerns the gene APOA2 and pancreatic neoplasm.